logo BDSP

Base documentaire

  1. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications.

    Article, Congrès - En anglais

    Identification and management of heterozygous familial hypercholesterolemia. Workshop. USA, 1992/07/20.

    When used for the primary prevention of coronary heart disease in persons with heterozygous familial hypercholesterolemia (hFH), a hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitor is projected to be effective and to have very favorable cost-effectiveness ratios at low-to-medium doses.

    For example, 20 mg of lovastatin per day is estimated to save lives and save money in all men ages 35-44 years with hFH and in women ages 35-44 years with hFH and any other risk factor.

    Mots-clés Pascal : Hypercholestérolémie, Maladie héréditaire, Homme, Hétérozygotie, Coût, Economie santé, Traitement, Chimiothérapie, Lovastatine, Hypolipémiant, Lipide, Cholestérol, Métabolisme pathologie, Hyperlipoprotéinémie

    Mots-clés Pascal anglais : Hypercholesterolemia, Genetic disease, Human, Heterozygozity, Costs, Health economy, Treatment, Chemotherapy, Antilipemic agent, Lipids, Cholesterol, Metabolic diseases, Hyperlipoproteinemia

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 94-0026623

    Code Inist : 002B22A. Création : 199406.